PressMarch 26, 2024 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
PressMarch 26, 2024 Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
PressMarch 20, 2024 MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
PressMarch 20, 2024 Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
PressMarch 20, 2024 Psyence Biomedical Ltd. Announces Results of Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
PressMarch 19, 2024 Filament Health Announces Shipments of Botanical Psilocybin to Four Countries for Clinical Investigation
PressMarch 19, 2024 Breakthrough in Wellness: Clearmind Medicine’s Psychedelic Treatment Granted Divisional Patent Approval in China
PressMarch 18, 2024 Red Light Holland Announces Happy Caps Mushroom Home Grow Kits Now Available in Over 270 Retail Stores Across Canada
PressMarch 18, 2024 Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
PressMarch 14, 2024 Clearmind Medicine Obtains Clearance for Its Psychedelic- Based Alcoholism Clinical Trial
PressMarch 14, 2024 ATMA CENA Psychedelic Healthcare Solutions Opens Psychedelic-Assisted Therapy Clinic in Calgary and Provides Update of its Clinic Network
PressMarch 14, 2024 Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
PressMarch 13, 2024 Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder
PressMarch 13, 2024 PharmaDrug’s SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine
PressMarch 13, 2024 Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
PressMarch 13, 2024 Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
PressMarch 12, 2024 Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
